Administration of the TLR9 antagonist ODN-2088 has been demonstrated to be an ideal treatment for several diseases, such as spinal cord injury, cerebral ischemia/reperfusion injury, liver injury and sepsis [22, 34–36]. This evidence concerns the gene TLR9 and digestive system neoplasm.